Nanoparticle Therapy Shows Promise Against Lung Cancer and Cancer-Related Muscle Wasting
A team of scientists has demonstrated a dual-action approach to treating lung cancer that may also address one of the disease's most debilitating complications. The experimental nanoparticle therapy delivers follistatin mRNA directly to tumors, where it reduced tumor growth in mice while simultaneously counteracting cachexia—a severe wasting condition that causes muscle loss and significantly worsens patient outcomes.
Cachexia affects a large proportion of advanced cancer patients and is notoriously difficult to treat. The condition contributes to frailty, reduces tolerance to cancer treatments, and is directly responsible for roughly 20–30% of cancer deaths. Current approaches have shown limited success in managing the syndrome.
The new therapy leverages lipid nanoparticles to carry follistatin mRNA specifically to tumor sites. Follistatin is a protein that inhibits myostatin, a signaling molecule that normally limits muscle growth. By delivering the therapy directly to tumors rather than systemic administration, the researchers aimed to maximize the effect on both cancer and muscle wasting while minimizing off-target effects.
In mouse models of lung cancer, treated animals showed reduced tumor growth alongside preservation of muscle mass compared to untreated controls. The dual mechanism represents a potential shift from treating cancer and its complications as separate problems toward addressing them simultaneously.
The findings remain preclinical, and translation to human patients will require extensive safety testing and clinical trials. However, the approach highlights an emerging strategy in oncology: designing therapies that attack tumors while also supporting the patient's overall physical condition.